Clinical outcome of a patient with lysosomal acid lipase deficiency and first results after initiation of treatment with Sebelipase alfa: A case report.
Dominik Soll, Dominik Spira, Tim Hollstein...
https://pubmed.ncbi.nlm.nih.gov/31249784/Actively Recruiting
Led by Alexion Pharmaceuticals, Inc. · Updated on 2026-03-06
300
Participants Needed
104
Research Sites
N/A
Total Duration
This research aims to collect detailed, long-term information about patients with Lysosomal Acid Lipase LAL Deficiency, a rare genetic disorder caused by a deficiency of the enzyme responsible for breaking down certain fats in the body. The condition can present as a severe and rapidly progressing disease in infants or a more chronic illness in children and adults, affecting the liver, spleen, and lipid levels, and leading to serious health complications including liver damage and cardiovascular risks. The study focuses on understanding the diseases natural history and variability to improve patient care worldwide. This is an observational, multi-center, international disease registry where patients diagnosed with LAL Deficiency, regardless of their treatment status, are followed over time. The registry collects real-world data to evaluate the long-term outcomes and effectiveness of treatments including sebelipase alfa. Participation is voluntary for both patients and physicians, and the study includes patients living with the disease as well as those deceased. Participants contribute data through their regular medical care and follow-up visits, with researchers gathering information about disease progression, treatment responses, and clinical outcomes. The primary goal is to enhance knowledge about LAL Deficiency by monitoring varied patient experiences and health changes over time. The study is ongoing and aims to support clinical practice and regulatory commitments related to sebelipase alfa therapy. The total duration of participation varies based on ongoing data collection.
CONDITIONS
Lysosomal Acid Lipase (LAL) Deficiency Registry
A
Alexion Pharmaceuticals, Inc. (Sponsor)
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Alexion Pharmaceuticals, Inc.
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or remote) for consent and eligibility confirmation
Duration - Up to several years depending on participation duration
Participants diagnosed with LAL Deficiency are observed to understand the variability, progression, and natural history of the disease.
Periodic visits as per routine clinical care and registry follow-up
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Dominik Soll, Dominik Spira, Tim Hollstein...
https://pubmed.ncbi.nlm.nih.gov/31249784/Manisha Balwani, William Balistreri, Lorenzo D'Antiga...
https://pubmed.ncbi.nlm.nih.gov/37222260/Lorenzo D'Antiga, Jennifer Evans, Emilio Ros...
https://pubmed.ncbi.nlm.nih.gov/40781810/Alexion Pharmaceuticals, Inc.
Lead Sponsor